A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: | Active, not recruiting |
---|---|
Conditions: | Colorectal Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 50 - Any |
Updated: | 3/2/2019 |
Start Date: | April 2015 |
End Date: | July 2020 |
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
This is a prospective longitudinal study to assess the impact of repeat Cologuard testing at
3 years in average risk patients.
3 years in average risk patients.
This is a prospective longitudinal study to assess the impact of repeat Cologuard testing at
3 years in average risk patients. Enrolled subjects will be prescribed Cologuard per approved
labeling at baseline. Subjects with positive results will be referred to colonoscopy and
study participation completed. Subjects with negative Cologuard results will be seen annually
for 3 years. At year 3, subjects will repeat Cologuard, followed by colonoscopy, regardless
of the Cologuard test outcome. Subjects who have a colonoscopy at any time during the study
will be discontinued following collection of the colonoscopy and associated histopathology
results.
3 years in average risk patients. Enrolled subjects will be prescribed Cologuard per approved
labeling at baseline. Subjects with positive results will be referred to colonoscopy and
study participation completed. Subjects with negative Cologuard results will be seen annually
for 3 years. At year 3, subjects will repeat Cologuard, followed by colonoscopy, regardless
of the Cologuard test outcome. Subjects who have a colonoscopy at any time during the study
will be discontinued following collection of the colonoscopy and associated histopathology
results.
Inclusion Criteria:
1. Subject has been prescribed Cologuard for colorectal cancer screening
2. Subject is at average risk for development of colorectal cancer
3. Subject is 50 years or older
4. Subject willing and able to sign informed consent.
Exclusion Criteria:
1. Subject had a colonoscopy in the previous 9 years
2. Subject has undergone any double-contrast barium enema, virtual (CT-based)
colonoscopy, or flexible sigmoidoscopy within the previous five (5) years.
3. Subject has had a positive fecal occult blood test or FIT within the previous six (6)
months.
4. Subject has any condition that in the opinion of the investigator should preclude
participation in the study (e.g., subject not eligible for a diagnostic colonoscopy).
5. Subject has a history of colorectal cancer or advanced adenoma.
6. Subject has a history of aerodigestive tract cancer
7. Subject has had a prior colorectal resection for any reason other than sigmoid
diverticular disease
8. Subject has had overt rectal bleeding, e.g. hematochezia or melena, within the
previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal
bleeding)
9. Subject has a diagnosis or personal history of any of the following high-risk
conditions for colorectal cancer:
- Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and
Crohn's disease.
- 2 first-degree relatives who have been diagnosed with colon cancer. (Note:
first-degree relatives include parents, siblings and offspring).
- One first-degree relative with CRC diagnosed before the age of 60.
10. Subject has a family history of:
- Familial adenomatous polyposis (also referred to as "FAP", including attenuated
FAP).
- Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC"
or "Lynch Syndrome").
- Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers
Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or
Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada
Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.
We found this trial at
40
sites
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Seth Crockett, MD
Phone: 919-445-0203
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
Click here to add this to my saved trials
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Robert S Kaufmann, MD
Phone: 678-702-0845
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Anas Daghestani
Phone: 512-421-4818
Click here to add this to my saved trials
Binghamton, New York 13901
Principal Investigator: Frank Eder, MD
Phone: 607-798-7345
Click here to add this to my saved trials
Carlsbad, California 92008
Principal Investigator: Gary Korff, MD
Phone: 760-547-2171
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: James Pritchard, MD
Phone: 513-488-1295
Click here to add this to my saved trials
Clearwater, Florida 33756
Principal Investigator: Miguel Trevino, MD
Phone: 727-584-6368
Click here to add this to my saved trials
Columbia, Maryland 21045
Principal Investigator: William Saway, MD
Phone: 704-996-4798
Click here to add this to my saved trials
Corona, California 92879
Principal Investigator: M. Mazen Jamal, MD
Phone: 951-220-4029
Click here to add this to my saved trials
Elkridge, Maryland 21075
Principal Investigator: Steven Geller, MD
Phone: 410-730-3399
Click here to add this to my saved trials
Endwell, New York 13760
Principal Investigator: Jonathan Harris, MD
Phone: 607-754-4081
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Glendale, Arizona 85308
Principal Investigator: Thomas Lenzmeier, MD
Phone: 623-295-1711
Click here to add this to my saved trials
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: Ibrahim Fakhouri, MD
Phone: 702-462-8822
Click here to add this to my saved trials
Homestead, Florida 33030
Principal Investigator: Michael Feldman, MD
Phone: 786-339-8454
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Thomas Imperiale, MD
Phone: 317-274-9321
Click here to add this to my saved trials
Jupiter, Florida 33458
Principal Investigator: Ronald Surowitz, DO
Phone: 561-741-2033
Click here to add this to my saved trials
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Folasade May, MD, PhD
Phone: 310-505-4077
Click here to add this to my saved trials
Click here to add this to my saved trials
Mesa, Arizona 85206
Principal Investigator: Tami Bruce, MD
Phone: 480-751-2480
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Newport Beach, California 92663
Principal Investigator: John Homan, MD
Phone: 760-421-2993
Click here to add this to my saved trials
Oxnard, California 93030
Principal Investigator: Augusto Focil
Phone: 805-483-1185
Click here to add this to my saved trials
Oxnard, California 93030
Principal Investigator: Karen Simon, MD
Phone: 805-483-1185
Click here to add this to my saved trials
Palm Springs, California 92262
Principal Investigator: Michael Jardula, MD
Phone: 760-320-9505
Click here to add this to my saved trials
Pompano Beach, Florida 33060
Principal Investigator: Daniel Lindenberg, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Seth Sweetser, MD
Phone: 507-538-1730
Click here to add this to my saved trials
Sacramento, California 95825
Principal Investigator: Kayvan Haddadan, MD
Phone: 888-543-2243
Click here to add this to my saved trials
Salt Lake City, Utah 84107
Principal Investigator: James Wood, MD
Phone: 801-288-0607
Click here to add this to my saved trials
Tempe, Arizona 85283
Principal Investigator: Thomas Fiel, DO
Phone: 480-831-6328
Click here to add this to my saved trials
Wooster, Ohio 45150
Principal Investigator: Raymond Mason, MD
Phone: 330-345-2008
Click here to add this to my saved trials
Click here to add this to my saved trials